Erwin Van Meir

Summary

Affiliation: Emory University
Country: USA

Publications

  1. pmc A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1
    S M Cork
    Department of Neurosurgery, Laboratory of Molecular Neuro Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Oncogene 31:5144-52. 2012
  2. pmc KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology
    Wei Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
    PLoS ONE 7:e44883. 2012
  3. pmc Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells
    M Tenan
    Laboratory of Tumor Biology and Genetics, Neurosurgery Department, University Hospital CHUV, 1011 Lausanne, Switzerland
    J Exp Med 191:1789-98. 2000
  4. pmc Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization
    Ainsley C Nicholson
    Laboratory of Molecular Neuro Oncology, Neurosurgery Department and Winship Cancer Institute, 1365 C Clifton Road, Room C5078, Emory University, Atlanta, GA 30322, USA
    BMC Evol Biol 5:11. 2005
  5. pmc Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma
    Erwin G Van Meir
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
    CA Cancer J Clin 60:166-93. 2010
  6. ncbi request reprint Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor
    Balveen Kaur
    Laboratory of Molecular Neuro Oncology, Departments of Neurosurgery, Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncogene 24:3632-42. 2005
  7. ncbi request reprint A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Neurosurgery Department and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncogene 22:2065-72. 2003
  8. ncbi request reprint Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion
    Giulia Fulci
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, Atlanta, GA 30322, USA
    Cancer Res 62:2897-905. 2002
  9. ncbi request reprint 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis
    Yuan Rong
    Department of Pathology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Neuropathol Exp Neurol 65:529-39. 2006
  10. pmc Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 69:2540-9. 2009

Detail Information

Publications58

  1. pmc A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1
    S M Cork
    Department of Neurosurgery, Laboratory of Molecular Neuro Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Oncogene 31:5144-52. 2012
    ....
  2. pmc KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology
    Wei Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
    PLoS ONE 7:e44883. 2012
    ..In conclusion, our preclinical data indicate that KCN1 is a potential therapeutic agent for pancreatic cancer, providing a basis for its future development...
  3. pmc Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells
    M Tenan
    Laboratory of Tumor Biology and Genetics, Neurosurgery Department, University Hospital CHUV, 1011 Lausanne, Switzerland
    J Exp Med 191:1789-98. 2000
    ..This downregulation may significantly contribute to glioblastoma development, since we show that an increase in TSP-1 expression is sufficient to strongly suppress glioblastoma cell tumorigenicity in vivo...
  4. pmc Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization
    Ainsley C Nicholson
    Laboratory of Molecular Neuro Oncology, Neurosurgery Department and Winship Cancer Institute, 1365 C Clifton Road, Room C5078, Emory University, Atlanta, GA 30322, USA
    BMC Evol Biol 5:11. 2005
    ....
  5. pmc Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma
    Erwin G Van Meir
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
    CA Cancer J Clin 60:166-93. 2010
    ....
  6. ncbi request reprint Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor
    Balveen Kaur
    Laboratory of Molecular Neuro Oncology, Departments of Neurosurgery, Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncogene 24:3632-42. 2005
    ..Modulation of this cleavage or delivery of Vasculostatin may constitute novel treatment modalities for cancer and other diseases of aberrant angiogenesis, especially in the brain...
  7. ncbi request reprint A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Neurosurgery Department and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncogene 22:2065-72. 2003
    ..This therapeutic approach can be used to treat all solid tumors that develop hypoxia, regardless of their tissue origin or genetic alterations...
  8. ncbi request reprint Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion
    Giulia Fulci
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, Atlanta, GA 30322, USA
    Cancer Res 62:2897-905. 2002
    ..They also suggest that astrocytoma initiation in this patient resulted from monoclonal evolution driven by a sequential loss of proapoptotic and growth arrest functions of p53...
  9. ncbi request reprint 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis
    Yuan Rong
    Department of Pathology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Neuropathol Exp Neurol 65:529-39. 2006
    ....
  10. pmc Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 69:2540-9. 2009
    ..These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens...
  11. pmc Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma
    Annalisa R Stone
    Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Rd, NE, Atlanta, GA 30322, USA
    Am J Pathol 165:1151-61. 2004
    ..The data suggest a role for the epigenetic silencing of TMS1 in the pathogenesis of human GBM. Methylation of TMS1 may prove to be a useful prognostic marker and/or predictor of patient survival and tumor malignancy...
  12. ncbi request reprint Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:8603-12. 2004
    ....
  13. pmc An integrative approach for in silico glioma research
    Lee A D Cooper
    Center for Comprehensive Informatics, Atlanta, GA 30322, USA
    IEEE Trans Biomed Eng 57:2617-21. 2010
    ..The preliminary results demonstrate the potential of combining morphometric and molecular characterizations for in silico research...
  14. pmc Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 66:7067-74. 2006
    ..We conclude that hypoxic up-regulation of tissue factor in glioblastoma multiforme cells depends largely on Egr-1 and is independent of HIF-1...
  15. pmc Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
    Balveen Kaur
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery and Hematology Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Neuro Oncol 7:134-53. 2005
    ..While HIF activation strongly promotes angiogenesis, the emerging vasculature is often abnormal, leading to a vicious cycle that causes further hypoxia and HIF upregulation...
  16. ncbi request reprint Cancer scene investigation: how a cold virus became a tumor killer
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Emory University School of Medicine, Emory University, 1365C Clifton Rd NE, Room C5068, Atlanta, GA 30322, USA
    Future Oncol 1:247-58. 2005
    ....
  17. ncbi request reprint Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model
    Seung Hee Kang
    Department of Hematology Oncology, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 66:11991-7. 2006
    ....
  18. pmc Brain cancer propagating cells: biology, genetics and targeted therapies
    Costas G Hadjipanayis
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Emory University, School of Medicine, Atlanta, GA 30322, USA
    Trends Mol Med 15:519-30. 2009
    ..Ultimately, treatments that include specific targeting of BCPCs might potentially be more effective at treating the entire tumor mass, translating to improved patient survival and quality of life...
  19. pmc Tumor initiating cells in malignant gliomas: biology and implications for therapy
    Costas G Hadjipanayis
    Departments of Neurosurgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 33022, USA
    J Mol Med (Berl) 87:363-74. 2009
    ..The development of new therapeutic strategies selectively targeting TICs while sparing NSCs may provide for more effective treatment of malignant gliomas...
  20. pmc Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism
    Balveen Kaur
    Department of Neurosurgery, Laboratory of Molecular Neuro Oncology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 69:1212-20. 2009
    ..These results advance the understanding of brain-specific angiogenic regulation, and suggest that Vstat120 has therapeutic potential in the treatment of brain tumors and other intracerebral vasculopathies...
  21. ncbi request reprint Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth
    Jaren W Landen
    Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:5187-201. 2004
    ....
  22. ncbi request reprint Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors
    Daniel J Brat
    Department of Pathology and Laboratory Medicine and Laboratory of Molecular Neuro Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Front Biosci 8:d100-16. 2003
    ..Thus, genetic events that occur during the progression of infiltrating astrocytomas promote angiogenesis, both by modulating hypoxia induced gene expression and by regulating of pro- and anti- angiogenic factors...
  23. ncbi request reprint Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation
    Daniel J Brat
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Adv Anat Pathol 9:24-36. 2002
    ..Understanding genetic events and their relation to angiogenic regulation in astrocytic neoplasms may eventually lead to therapies that are specifically directed at molecularly defined subsets of these diseases...
  24. pmc Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression
    Balveen Kaur
    Laboratory of Molecular Neuro Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Am J Pathol 162:19-27. 2003
    ..The finding that expression of BAI proteins may be lost during tumor formation is of special interest as restoration of their function in tumors may be of therapeutic benefit...
  25. ncbi request reprint Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population
    Daniel J Brat
    Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 64:920-7. 2004
    ....
  26. ncbi request reprint Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma
    Daniel J Brat
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine H 176, 1364 Clifton Road NE, Atlanta, GA 30322, USA
    Lab Invest 84:397-405. 2004
    ..Since the hypoxic induction of angiogenesis appears to support further neoplastic growth, therapeutic targeting of the underlying vascular pathology and thrombosis could provide a new means to prolong time to progression...
  27. ncbi request reprint Emerging molecular therapies for brain tumors
    Erwin G Van Meir
    Department of Neurosurgery, Winship Cancer Institute Brain Tumor Program, Emory University, Atlanta, GA 30322, USA
    Semin Oncol 31:38-46. 2004
    ..These findings are now being translated into innovative clinical trials that provide new hope for patients with these devastating diseases...
  28. ncbi request reprint Replicative oncolytic herpes simplex viruses in combination cancer therapies
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Curr Gene Ther 4:41-51. 2004
    ..In this review, we focus on the oncolytic Herpes Simplex Virus-1 (HSV-1) vectors that have been examined in preclinical and clinical cancer models and their use in combination with chemo-, radio-, and gene therapies...
  29. ncbi request reprint Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration
    Fatima W Khwaja
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 12:6331-6. 2006
    ..The goal of our study was to find reliable markers that could be used for disease monitoring as well as to identify new targets for the therapeutic intervention for malignant astrocytoma (WHO grades 3 and 4)...
  30. ncbi request reprint Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway
    Chalet Tan
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Res 65:605-12. 2005
    ..Further studies on the mechanism of action of 103D5R will likely provide new insights into its validity/applicability for the pharmacologic targeting of HIF-1alpha for therapeutic purposes...
  31. ncbi request reprint Genetic and hypoxic regulation of angiogenesis in gliomas
    Balveen Kaur
    Laboratory of Molecular Neuro Oncology, Department of Neuro surgery and Hematology Oncology, and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Neurooncol 70:229-43. 2004
    ..This review will summarize the properties of angiogenic dysregulation that lead to the highly vascularized nature of these tumors...
  32. ncbi request reprint PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 65:1406-13. 2005
    ....
  33. pmc Identification of a novel small molecule HIF-1alpha translation inhibitor
    Takuhito Narita
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 15:6128-36. 2009
    ..HIF-1 is overexpressed in cancer and has become an important therapeutic target in solid tumors. In this study, a novel HIF-1alpha inhibitor was identified and its molecular mechanism was investigated...
  34. ncbi request reprint Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion
    Anita C Bellail
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Hematology Oncology, Winship Cancer Institute and Brain Tumor Program, Emory University, Atlanta, GA 30322, USA
    Int J Biochem Cell Biol 36:1046-69. 2004
    ..This review will focus on the impact of microregional heterogeneity of the ECM on glioma invasion in the normal adult brain and its modifications in tumoral brain...
  35. pmc The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
    Daniel J Brat
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Neuro Oncol 7:122-33. 2005
    ..A precise definition of the mechanisms by which IL-8 exerts its proangiogenic functions requires further study for the development of effective IL-8-targeted therapies...
  36. ncbi request reprint Replicative oncolytic adenoviruses in multimodal cancer regimens
    Dawn E Post
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Hum Gene Ther 14:933-46. 2003
    ..In this review, we describe the oncolytic Ad vectors tested in preclinical and clinical models and their use in combination with chemo-, radio-, and gene therapies...
  37. ncbi request reprint Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review)
    Stephen B Hunter
    Department of Pathology and Laboratory Medicine, Emory University Hospital, H 173, NE, Atlanta, GA 30322, USA
    Int J Oncol 23:857-69. 2003
    ..Although at the present no molecular system for the classification of brain tumors has been generally accepted, microarray technologies offer the exciting prospect of practical molecular classification in the future...
  38. pmc Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4
    Dawn E Post
    Department of Neurosurgery, Winship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road, Atlanta, GA 30322, USA
    Cancer Res 67:6872-81. 2007
    ....
  39. pmc Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients
    Fatima W Khwaja
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery and Winship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road NE, Atlanta, GA 30322, USA
    J Proteome Res 6:559-70. 2007
    ....
  40. pmc BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
    Karen H Ventii
    Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Res 68:6953-62. 2008
    ..The identification of the deubiquitinating enzyme BAP1 as a tumor suppressor may lead to further understanding of how the ubiquitin proteasome system contributes to cancer and aid in the identification of new targets for cancer therapy...
  41. ncbi request reprint Inhibitors of hypoxia-inducible factor-1 signaling
    Vladimir E Belozerov
    Emory University, Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Winship Cancer Institute, 1365C Clifton Road, Atlanta, GA 30322, USA
    Curr Opin Investig Drugs 7:1067-76. 2006
    ..This review describes the progress toward the identification of specific inhibitors of HIF-1, and discuss the first examples of HIF-1-targeted therapeutics to enter clinical development...
  42. ncbi request reprint Hypoxia inducible factor-1: a novel target for cancer therapy
    Vladimir E Belozerov
    Department of Neurosurgery, Hematology Oncology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Anticancer Drugs 16:901-9. 2005
    ..These drugs disrupt the HIF-1 signaling pathway through a variety of mechanisms, including the inhibition of HIF-1alpha protein synthesis, stabilization, nuclear translocation and HIF-1 transactivation of target genes...
  43. ncbi request reprint Use of replicating oncolytic adenoviruses in combination therapy for cancer
    Roland L Chu
    Laboratory of Molecular Neuro Oncology, Departments of Neurosurgery, Hematology Oncology, and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Clin Cancer Res 10:5299-312. 2004
    ..This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy...
  44. pmc Proteomics of gliomas: initial biomarker discovery and evolution of technology
    Juliya Kalinina
    Laboratory of Molecular Neuro Oncology, Departments of Neurosurgery, Hematology and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 13:926-42. 2011
    ....
  45. ncbi request reprint Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers
    Fatima W Khwaja
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA 30322, USA
    Proteomics 6:6277-87. 2006
    ..3-13.7 kDa peak range in non-neoplastic CSF and was most prominent in inflammatory conditions. Our approach provides a rational basis for identifying biomarkers that could be used for detection, diagnosis, and monitoring of CNS diseases...
  46. pmc Natural mutagenesis of human genomes by endogenous retrotransposons
    Rebecca C Iskow
    Genetics and Molecular Biology Graduate Program, Emory University, Atlanta, GA 30322, USA
    Cell 141:1253-61. 2010
    ..Our data indicate that transposon-mediated mutagenesis is extensive in human genomes and is likely to have a major impact on human biology and diseases...
  47. ncbi request reprint PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion
    Jee Yin Ahn
    Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 279:16441-51. 2004
    ..Our results demonstrate that PIKE-A is a physiologic regulator of Akt and an oncogenic effector of cell invasion...
  48. ncbi request reprint Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 62:2478-82. 2002
    ..Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells...
  49. ncbi request reprint Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1
    Michele Albertoni
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hosptial Lausanne, 1011 Lausanne, Switzerland
    Oncogene 21:4212-9. 2002
    ..Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities...
  50. ncbi request reprint Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma
    Michael Kragh
    Laboratory of Experimental Oncology, University of Copenhagen, DK 2100 Copenhagen, Denmark
    Cancer Res 62:1191-5. 2002
    ..Elucidation of the mechanisms that allow this to happen has important consequences for the understanding of tumor recurrence after antiangiogenic therapy...
  51. doi request reprint Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment
    Hongsung Kim
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Methodist Hospital, Houston, Texas 77030, USA
    Mol Ther 16:599-606. 2008
    ..Hypoxia-resistant T cells may thus be of value in the treatment of human tumors in which areas of hypoxia may otherwise account for resistance to this therapeutic strategy...
  52. ncbi request reprint Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1
    Ella Kim
    Department of Neurosurgery, University Hospital Lubeck, Lubeck, Germany
    Oncogene 22:7716-27. 2003
    ..An important implication of our findings is that the loss of p53-mediated negative control over ets-1-dependent transcription may lead to the acquisition of an invasive phenotype in tumor cells...
  53. ncbi request reprint TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways
    Jin H Song
    Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
    Brain Pathol 13:539-53. 2003
    ....
  54. ncbi request reprint Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells
    Charles S Cobbs
    Surgical Service, Veterans Affairs Medical Center, University of Alabama at Birmingham Department of Surgery, Division of Neurosurgery, Birmingham, Alabama 35294, USA
    Cancer Res 63:8670-3. 2003
    ..Concentrations of peroxynitrite associated with a tumor inflammatory environment caused dysregulation of wild-type p53 transcriptional activity and downstream p21(WAF1) expression...
  55. ncbi request reprint Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy
    Yueh Chun Li
    Department of Biomedical Sciences, Chung Shan Medical University, Taichung, Taiwan
    Clin Cancer Res 12:2716-29. 2006
    ..Many human malignant glioma cells, however, are resistant to TRAIL treatment. We, therefore, investigated the genomic alterations in TRAIL-resistant malignant glioma cells...
  56. ncbi request reprint Absence of KLF6 gene mutations in human astrocytic tumors and cell lines
    Pasi A Koivisto
    Int J Cancer 111:642-3. 2004

Research Grants23

  1. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin G Van Meir; Fiscal Year: 2010
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  2. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2009
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  3. Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors
    Erwin Van Meir; Fiscal Year: 2009
    ..These preclinical studies have the potential to directly benefit human health by increasing the survival of cancer patients, a main goal of the National Cancer Institute. ..
  4. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2002
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  5. A hypoxia-dependent adenovirus for glioma therapy
    Erwin Van Meir; Fiscal Year: 2002
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of cancer patients. ..
  6. Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors
    Erwin G Van Meir; Fiscal Year: 2010
    ..These preclinical studies have the potential to directly benefit human health by increasing the survival of cancer patients, a main goal of the National Cancer Institute. ..
  7. Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors
    Erwin Van Meir; Fiscal Year: 2009
    ..These preclinical studies have the potential to directly benefit human health by increasing the survival of cancer patients, a main goal of the National Cancer Institute. ..
  8. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2009
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  9. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2001
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  10. Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors
    Erwin Van Meir; Fiscal Year: 2007
    ..These preclinical studies have the potential to directly benefit human health by increasing the survival of cancer patients, a main goal of the National Cancer Institute. ..
  11. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2007
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  12. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2002
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  13. A hypoxia-dependent adenovirus for glioma therapy
    Erwin Van Meir; Fiscal Year: 2003
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of cancer patients. ..
  14. Hypoxia as a target for the treatment of brain tumors
    Erwin Van Meir; Fiscal Year: 2003
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of children and adults with cancer. ..
  15. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2003
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  16. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2004
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  17. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2003
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  18. A hypoxia-dependent adenovirus for glioma therapy
    Erwin Van Meir; Fiscal Year: 2004
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of cancer patients. ..
  19. A hypoxia-dependent adenovirus for glioma therapy
    Erwin Van Meir; Fiscal Year: 2005
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of cancer patients. ..
  20. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin G Van Meir; Fiscal Year: 2011
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..